UK Cardiac Pacemakers Market Report 2023 to 2030

UK Cardiac Pacemakers Market Analysis

$ 3999

The UK Cardiac Pacemakers Market was valued at $105.22 Mn in 2023 and is predicted to grow at a CAGR of 1.2% from 2023 to 2030, to $114.38 Mn by 2030. The key drivers of this industry include increasing aging population, advancements in technology, and supportive government initiatives. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.

ID: IN10GBMD013 CATEGORY: Medical Devices GEOGRAPHY: UK AUTHOR: Aashwi Mehta

Buy Now

UK Cardiac Pacemakers Market Executive Summary

The UK Cardiac Pacemakers Market was valued at $105.22 Mn in 2023 and is predicted to grow at a CAGR of 1.2% from 2023 to 2030, to $114.38 Mn by 2030.

A pacemaker is a small device used to manage certain types of arrhythmias, which can cause the heart to beat too fast (tachycardia), too slow (bradycardia), or irregularly. When the heart beats too slowly, it can lead to insufficient oxygen supply to the body and brain, resulting in symptoms like dizziness, fatigue, fainting, and breathlessness. Pacemakers function by delivering electrical pulses to regulate and stabilize the heart rate and rhythm. They also help coordinate the pumping action of the heart chambers, enhancing the efficiency of blood circulation, particularly beneficial for individuals with heart failure.

In the UK, approximately 7.6 Mn people live with heart and circulatory diseases, including about 4 Mn men and 3.6 Mn women. These conditions account for roughly 27% of all deaths in the country, resulting in over 170,000 fatalities annually, or 480 deaths each day—equivalent to one every three minutes. The market is driven by significant factors like increasing aging population, advancements in technology, and government initiatives. However, cost constraints, pacemaker infection, and availability of alternative therapies restrict the growth and potential of the market.

Prominent players in this field include Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.

UK Cardiac Pacemakers Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Aging Population: The UK's significant aging population, currently over 11 Mn people aged 65 and projected to reach 13 Mn within a decade (22% of the population), is a major market driver for cardiac pacemakers. This demographic trend indicates a higher incidence of age-related heart conditions, which increases the demand for pacemakers to manage these issues effectively, thereby driving market growth.

Advancements in Technology: The adoption of newer, less invasive pacemaker technologies, such as leadless pacemakers, is on the rise and driving market growth in the UK. These advanced devices offer benefits like reduced surgical risks and quicker recovery times, making them more appealing to both patients and healthcare providers, thereby boosting the demand for pacemakers.

Government Initiatives: The NHS (National Health Service) Long Term Plan designates cardiovascular disease as a top clinical priority and the leading condition where the NHS can save the most lives over the next decade. The Plan aims to prevent over 150,000 heart attacks, strokes, and dementia cases by 2029. This focus and ambition drive the cardiac pacemakers market in the UK, as increased efforts in prevention and treatment of cardiovascular diseases boost the demand for pacemakers.

Market Restraints

Cost Constraints: The high cost of pacemaker devices and implantation procedures can be prohibitive, limiting access and adoption, particularly in healthcare settings with budget constraints. This financial barrier acts as a market restraint for the cardiac pacemakers market in the UK, as it restricts the number of patients who can afford the treatment.

Pacemaker Infection: The pacemaker-related complications, such as infections, bradycardia, and blood clots, significantly restrains the overall growth of the cardiac pacemaker market in the UK. These issues can deter patients and healthcare providers from opting for pacemaker treatments, thereby limiting market expansion.

Availability of Alternative Therapies: The availability of alternative therapies serves as a market restraint for the cardiac pacemakers market in the UK because it provides patients with other treatment options for managing heart conditions. Alternatives such as medication, catheter ablation, and implantable cardioverter-defibrillators (ICDs) can decrease the demand for pacemakers, hindering market growth.

Regulatory Landscape and Reimbursement Scenario

In the UK, cardiac pacemakers are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has issued guidance on the design of pre- and post-market clinical studies for leadless cardiac pacemaker therapy. This guidance applies to new devices as well as any design changes or iterations that could impact the clinical safety or performance of the leadless pacemaker. In the UK, cardiac pacemakers are reimbursed under the National Health Service (NHS) payment by results system. Hospitals receive reimbursement for services provided through Health Resource Groups (HRG) codes.

Competitive Landscape

Key Players

Here are some of the major key players in the Cardiac Pacemaker Market:

Abbott Laboratories
Biotronik
Boston Scientific
Medtronic
Edwards Lifesciences
Siemens Healthineers
OSYPKA Medical
MicroPort Scientific Corporation
LivaNova
Cardinal Health

1. Executive Summary
1.1 Device Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Regulatory Landscape for Medical Device
1.6 Health Insurance Coverage in Country
1.7 Type of Medical Device
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Cardiac Pacemakers Market Segmentation

By Product Type

Single chamber
Dual chamber
Bi ventricular

By Application

Bradycardia
Tachycardia
Other Arrhythmia

By End Users

Hospitals
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.